ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies

Sherr, Jennifer; Tauschmann, Martin; Battelino, Tadej; Bock, Martin de; Forlenza, Gregory P.; Román, Rossana; Hood, Korey K.; Maahs, David M.

doi:10.1111/pedi.12731

Cited by 177 publications

(189 citation statements)

References 313 publications

(607 reference statements)

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Established guidelines recommend the use of CGM and its benefits in people with Type 1 diabetes have been demonstrated . Furthermore, a small number of qualitative studies examining people's experiences with CGM are available .…”

Section: Introductionmentioning

confidence: 99%

Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents’ perspective

et al. 2019

View full text Add to dashboard Cite

Aim Remote monitoring with continuous glucose monitoring (CGM) in children with Type 1 diabetes mellitus has recently become available, but little is known about caregivers’ experiences of its use, particularly in younger children. The aim of this study was to explore parents’ everyday experiences of using this technology. Methods The parents of children with Type 1 diabetes diagnosed for > 1 year, aged 2–12 years were invited to participate in a semi‐structured interview. Interviews were the second phase of a randomized cross‐over study using standard insulin therapy with or without CGM and remote monitoring for two 3‐month periods. Open‐ended questions were used to explore parents’ real‐life experiences of the remote monitoring and CGM system. Interviews were analysed using thematic analysis. Results Five themes related to remote monitoring emerged: (i) impact on sleep quality for the parents, (ii) peace of mind, (iii) impact on anxiety, (iv) freedom and confidence for the parents and children, and (v) impact on relationships. Furthermore, parents reported on themes related to CGM in general, such as better understanding of how to manage and control their child's diabetes and experiences related to physical or technical aspects. Conclusion Overall, parents of primary school children reported that using remote monitoring and CGM was a mostly beneficial experience. However, negative aspects within the themes were also reported. These findings will help to provide a structure to discuss parent and child expectations and provide targeted education at the start of using remote monitoring and CGM.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents’ perspective

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A greater frequency of finger prick glucose monitoring improves diabetes control due to better insulin dosing for meals and corrections of out‐of‐target glucose values. ISPAD guidelines recommend a finger prick blood glucose test be performed 6‐10 times per day in children with T1D . To cover such frequent SMBG measurements, 180‐300 strips/month should be used (and reimbursed to avoid socioeconomically driven differences in the prognosis of T1D in children in the given country).…”

Section: Discussionmentioning

confidence: 97%

Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective

et al. 2019

View full text Add to dashboard Cite

Background Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. Methods The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. Results We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. Conclusions Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.

show abstract

“…In 2018, the International Society for Pediatric and Adolescent Diabetes (ISPAD) released its first set of diabetes technology guidelines as a separate chapter. 30 These guidelines contain a section specifically addressing diabetes apps, ADS, and bolus calculators. The executive summary of the ADS from the guidelines was ''Automated algorithmic adjustment of openloop pump settings and insulin dosing parameters is an emerging area of research and clinical care in diabetes technology (E).…”

Section: Guidelines On Ads Technologymentioning

confidence: 99%

Use of Artificial Intelligence to Improve Diabetes Outcomes in Patients Using Multiple Daily Injections Therapy

Forlenza

2019

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies

Cited by 177 publications

References 313 publications

Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents’ perspective

Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents’ perspective

Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective

Use of Artificial Intelligence to Improve Diabetes Outcomes in Patients Using Multiple Daily Injections Therapy

Contact Info

Product

Resources

About